Listen
Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the new indication (moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies).
-
Clinical Benefit
| Substantial |
The actual benefit of this proprietary medicinal product is substantial. |
Clinical Added Value
| no clinical added value |
HUMIRA does not provide any improvement in actual benefit (IAB V) in the treatment of active, moderate to severe ulcerative colitis which is intolerant or respond inadequately to conventional treatments (corticosteroids, azathioprine or 6-mercaptopurine). |
English version
Contact Us
Évaluation des médicaments
